OPKO Health, Inc.

Equities

OPK

US68375N1037

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-25 EDT			5-day change	1st Jan Change
1.29 ^USD	-1.53%		+2.38%	-14.57%

05-07	Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	MT
05-07	Opko Health, Inc. Provides Earnings Guidance for the Second Quarter of 2024	CI

OPKO Health : Introduction of Scarlet Health™ In=Home Diagnostic Service

January 13, 2021 at 04:44 pm

Introduction of Scarlet Health™ In-Home Diagnostic Service

Jan 13, 2021

Attachments

Original document
Permalink

Disclaimer

Opko Health Inc. published this content on 13 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2021 21:43:05 UTC

Latest news about OPKO Health, Inc.

Earnings Flash (OPK) OPKO HEALTH Posts Q1 Revenue $173.7M, vs. Street Est of $183M	05-07	MT
Opko Health, Inc. Provides Earnings Guidance for the Second Quarter of 2024	05-07	CI
Transcript : OPKO Health, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
OPKO Health, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Laboratory Corp of America to Acquire BioReference's Diagnostics Business Select Assets	03-28	MT
Transcript : OPKO Health, Inc. - Shareholder/Analyst Call	03-28
Entera Bio Announces Robust Pharmacokinetic Data for First-In-Class Oral Glp-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome	03-20	CI
Opko Health Insider Bought Shares Worth $444,300, According to a Recent SEC Filing	03-14	MT
Opko Health Insider Bought Shares Worth $463,750, According to a Recent SEC Filing	03-13	MT
Opko Health Insider Bought Shares Worth $559,380, According to a Recent SEC Filing	03-12	MT
Barrington Cuts Price Target on OPKO Health to $1.50 From $2, Maintains Outperform Rating	02-28	MT
Transcript : OPKO Health, Inc., Q4 2023 Earnings Call, Feb 27, 2024	02-27
Earnings Flash (OPK) OPKO HEALTH Reports Q4 Revenue $181.9M, vs. Street Est of $177.5M	02-27	MT
OPKO Health, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-27	CI
Drugmakers deepen efforts to tap into booming market for obesity drugs	02-27	RE
Opko Health Insider Bought Shares Worth $991,700, According to a Recent SEC Filing	02-21	MT
HealthSnap, Inc. announced that it has received $24.999999 million in funding from a group of investors	02-20	CI
OPKO Health, Inc. Announces the Cessation of Alexis Borisy as Member of the Board of Directors and Member of Compensation Committee of the Board	02-09	CI
NextPlat Preparing to Launch Opko Health Store on Alibaba's Tmall Global Platform	02-05	MT
Opko Health Insider Bought Shares Worth $488,650, According to a Recent SEC Filing	01-19	MT
Opko Health Insider Bought Shares Worth $386,200, According to a Recent SEC Filing	01-18	MT
Opko Health Insider Bought Shares Worth $954,300, According to a Recent SEC Filing	01-16	MT
Opko Health Insider Bought Shares Worth $480,379, According to a Recent SEC Filing	01-11	MT
Transcript : OPKO Health, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM	01-10
OPKO Health Closes Private Offering of $230 Million Convertible Notes Due 2029	01-09	MT

Chart OPKO Health, Inc.

Duration

Period

More charts

Company Profile

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Sector

Healthcare Facilities & Services

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for OPKO Health, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.29 USD

Average target price

4.25 USD

Spread / Average Target

+229.46%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
OPKO HEALTH, INC.	-14.57%	913M
SONIC HEALTHCARE LIMITED	-18.80%	8.49B
RADNET, INC.	+65.89%	4.29B
DR. LAL PATHLABS LIMITED	+5.48%	2.68B
SYNLAB AG	-1.93%	2.63B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-57.14%	1.73B
NEOGENOMICS, INC.	-19.16%	1.68B
FLEURY S.A.	-20.01%	1.45B
METROPOLIS HEALTHCARE LIMITED	+15.38%	1.19B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-50.40%	1.01B

Medical & Diagnostic Laboratories